Zydus Cadila gets three USFDA approvals
Cadila Healthcare group has received approvals from the United States Food and Drug Association (USFDA) to market three products in quick succession namely, Lamotrigine Chewable Tablets of 2 mg, 5 mg and 25 mg, Lamotrigine Tablets of 25 mg, 50 mg and 150 mg and Divalproex Sprinkle Capsules 125 mg. The Company will market all … Read more Zydus Cadila gets three USFDA approvals